Instil Bio is no longer a cell-therapy or bispecific developer. After its Axion Bio subsidiary halted the former lead antibody and returned the license to ImmuneOnco in January, the Dallas issuer is a Nasdaq-listed search vehicle sitting on a California factory leased to AstraZeneca and a balloon mortgage that comes due before cash on hand can repay it. The June quarter is the first full period of that empty-pipeline state. What changed is not a clinical readout. What changed is the absence of a product.
The cost collapse is real and almost complete. Operating expenses fell to the mid single millions from more than $20 million in the year-ago quarter, as research spend dropped to a residual trickle and the prior-year ImmuneOnco milestone did not repeat. The remaining engine is straight-line rent from the Tarzana campus, which covers part of interest and none of the public-company overhead. Cash, restricted cash, and Treasuries sit near $70 million. The Midland National loan principal sits above $85 million. Shareholders therefore own a leveraged real-estate stub plus an option on whatever management next licenses.
The market already treats that option as nearly worthless. Equity value near $48 million sits well below book equity above $100 million. It also sits well below the carrying value of the factory after the May decision to stop marketing it for sale. The bear case is that a January maturity, a thin float, and two abandoned platforms leave little room for a clean in-license. The bull case is that the contractual extension option and a cash runway that management says funds the current plan beyond next year buy time to buy an asset without a desperate raise. The next test is whether that extension is exercised and whether a named candidate appears before search costs eat the cushion.